Premium
[O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE
Author(s) -
Budur Kumar,
West Tim,
Braunstein Joel B.,
Fogelman Ilana,
Bordelon Yvette M.,
Litvan Irene,
Roberson Erik D.,
Hu Helen,
Verghese Philip B.,
Bateman Randall J.,
Florian Hana,
Wang Deli,
Ryman Davis,
Gault Laura,
Goss Sandra,
Mendonca Nuno,
RendenbachMueller Beatrice,
Kerwin Diana R.,
Boxer Adam L.,
Holtzman David M.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.241
Subject(s) - tolerability , medicine , placebo , cmax , pharmacokinetics , adverse effect , progressive supranuclear palsy , surgery , anesthesia , atrophy , pathology , alternative medicine
computerized tests and traditional neuropsychological tests to predict amyloid status will be presented along with cognitive results for additional participants. Conclusions:Our findings demonstrate the validity of the ReVeRe cognitive test battery, including the first successful automation and validation in clinic and at home of a test of verbal memory using speech recognition software. Such tests will enable widespread testing in home, primary care, and clinical trial settings and improve identification of patients in the earliest stages of AD.